Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
ConclusionsImmune-related adverse effects often occur within 3 –6 months of receiving immune checkpoint inhibitor therapy, with some reports of late toxicity. This report highlights a case of probable neurosarcoidosis nearly a year after discontinuation of immune checkpoint therapy. The potential for durable responses after discontinuation of therapy also li kely underscores a potential for late toxicity. In patients presenting with new or unexplained symptoms after checkpoint inhibitor therapy, the index of suspicion for an immune-related adverse effect should remain high, irrespective of timing.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Immunotherapy | Melanoma | Methotrexate | Neurology | Radiography | Remicade | Sarcoidosis | Skin Cancer | Toxicology | Yervoy